VIM and esophageal squamous cell carcinoma: Taken together, these rescue experiments demonstrate that fedratinib suppresses ESCC progression through the JAK2/STAT3 pathway by downregulating vimentin, cyclin D1, and survivin, leading to concurrent inhibition of proliferation and migration, along with induction of apoptosis.